**Core Concept**
The question is testing the understanding of the pharmacological features of "prototype drugs" and "me-too drugs." Prototype drugs are the first drugs to be developed for a specific therapeutic class, while me-too drugs are similar drugs developed later to compete with the prototype drug. The pharmacological feature being tested is related to their mechanism of action.

**Why the Correct Answer is Right**
Both prototype and me-too drugs have a similar mechanism of action, as they target the same receptor or enzyme to produce their therapeutic effect. This similarity in mechanism of action is a key characteristic of me-too drugs, as they are designed to be similar to the prototype drug but with minor modifications. The similarity in mechanism of action is essential for me-too drugs to be effective and safe for patients.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because the pharmacokinetic profiles of prototype and me-too drugs are not similar. Me-too drugs often have different pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, to differentiate them from the prototype drug.
* **Option B:** This option is incorrect because the safety profiles of prototype and me-too drugs are not similar. Me-too drugs may have different side effect profiles or toxicity profiles compared to the prototype drug.
* **Option C:** This option is incorrect because the dosing regimens of prototype and me-too drugs are not similar. Me-too drugs may require different dosing regimens or frequencies to achieve the same therapeutic effect.

**Clinical Pearl / High-Yield Fact**
Me-too drugs are often developed to target specific patient populations or to address specific concerns, such as reduced side effects or improved efficacy.

**Correct Answer: C.**